Symphogen closes 33M-euro financing

Denmark's Symphogen A/S has closed a 33.0-million euro ($42.3 million) financing. Existing investors participated in the round, which was led  by Essex Woodlands Health Ventures. The proceeds will be used to mature  the company's product pipeline of antibody therapeutics, particularly  within the field of oncology.

"This significant financial commitment from our current investors  demonstrates their confidence in Symphogen's innovative pipeline and  antibody discovery and manufacturing technologies," said Kirsten Drejer,  chif executive. "The current funding will support the advancement of our  lead oncology program, Sym004, towards early clinical studies as  Symphogen continues to build a competitive oncology franchise.  Coinciding with our strategic decision to focus our internal R&D  resources on further maturing our oncology pipeline, Symphogen also  plans to broaden our external collaborative activities by engaging in  partnership discussions for our anti-RSV and anti-RhD recombinant  polyclonal antibody programs," he added.